Johnson & Johnson JNJ

$266.30 +2.49 (0.94%)

Valuation

Market cap
635,072,512,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
25.13
Forward PE
24.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,777,400
Avg volume
6,979,752
Day's range
$264.97 – $272.36
Shares out
2,407,310,000
Stochastic %K
75%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

DoubleUpwithChuck Oct 27, 5:19 AM
$JNJ $GSK $PFE $ABBV I think our buyer will be pharma. Quantum companies are looking at them like ripe customers. They need to buy Zapata now
0 replies
TopOptionAlert Oct 27, 2:48 AM
$JNJ NOV20 275C · still actionable Zone: $264.44 to $268.16 Invalidation: close under $262.40 Objectives: $272.36, then $281.07 The math: up 2.3% to the first objective and 5.5% to the second, against 1.5% risk on the invalidation, better than 3 to 1 to the second. Dear friend, picture a steady shop that climbed from 257 dollars and 78 cents last Wednesday to 266 dollars and 30 cents on Monday, holding above its 50 day average. Johnson and Johnson beat its October 13 earnings estimate and raised its full year sales outlook to 101.2 billion dollars, a plain sign the big drug business is carrying the load. This swing simply rides that steady climb, toward the Monday high first and then toward the high for the year, while a close under the Friday low says the climb has stalled and you step aside. P.S. Watch 272 dollars and 36 cents, the Monday high, because a move over it shows buyers pushing past the recent top.
0 replies
whymystockmoved Oct 27, 12:41 AM
$ORIC fell about 32% to $8.96 on Monday; we found no ORIC release or filing that day. Over the weekend, Johnson & Johnson reported early results for JNJ-6143, a pill for the same advanced prostate cancer that ORIC's lead drug, rinzimetostat, targets. A Leerink analyst said the data raise the competitive threat to rinzimetostat. The catch: the two drugs haven't been compared in the same trial, and ORIC has its own Phase 3 under way. Full breakdown: https://whymystockmoved.com/stocks/oric/2026-10-26-why-oric-pharmaceuticals-stock-fell/ $JNJ
0 replies
TearsForFear Oct 26, 7:47 PM
$IBRX @AztecPyramid I’m thinking e’s will be just fine. $JNJ should be worried Hugely about anktiva in bcg naive treatment. Anktiva First mover Advantage will put jnj in dog house for
0 replies
TitanMoonofSaturn Oct 26, 7:33 PM
$JNJ $AVR J&J has spent roughly $30B building a heart business and still doesn't have a valve. Abiomed: ~$16.6B (2022) Shockwave: ~$13.1B (2024) Laminar: $400M upfront (2023) Atraverse: announced this year And Q3 wasn't pretty. MedTech grew 2.5%, below their own targets. Cardio slowed to 4.3% after running double digits. Abiomed actually shrank 2.3%. Schmid: "we can do better, and we absolutely will." That's heart recovery, circulation, rhythm and LAA covered. No TAVR. They're the only major cardio player sitting out one of the biggest device markets in cardiology. Everyone else is picking a balloon-expandable bet. BSX put $1.5B into MiRus. Medtronic took a stake in Anteris. Abbott is building its own, still at 11 patients in feasibility. Wolk on the call: "We always are on the lookout for strategic drivers that could complement our business." Not many independent BE platforms with real data left, let alone differentiated like duravr! This is masqueraded on purpose imo
5 replies
MMoe1010 Oct 26, 7:06 PM
$IBRX $JNJ
0 replies
HboFam Oct 26, 6:49 PM
$AZN $BMY $JNJ $SLS taking wagers the bogus billionaire biostatistician pumps are all a set up for another short rug pull when the 80th is announced kalshi odds 100% on @SellasgpsCurativeBAT11 tony the tiger will be so “scared“ he's gonna sell it all - again- After the 80th
1 replies
TearsForFear Oct 26, 6:39 PM
$IBRX By locking its database for the BCG-naive trial and eyeing additonal label expansions, the battle for market share Vs $JNJ is really just hitting its stride as both companies push for positioning ahead of wider adoption. Moving into the BCG-naive population is the ultimate prize because that's where the vast majority of early-stage bladder cancer patients land first, bypassing the "unresponsive" stage entirely. Instead of catching patients after standard BCG has already failed them, Anktiva plus BCG could become part of the initial standard of care right out of the gate. That dramatically expands the addressable patient pool and cuts out months or years of trial-and-error treatments. Unlike J&J's TAR-200 localized gemcitabine device system, Anktiva’s mechanism is designed to enhance standard BCG by driving both innate and adaptive immune memory. If urologists can use Anktiva alongside regular BCG with superior durable response rates shifting the mkt preference heavily in its favor.
1 replies